TMCnet News
Vericel to Host Analyst and Investor Day on April 11, 2018CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on April 11, 2018 in New York City from 8:30 a.m. – 11:00 a.m. ET. Vericel executives will provide business updates and facilitate discussions with surgeon thought leaders who currently use Vericel products in their practices. Also speaking will be world champion swimmer, best-selling author, five-time Olympian and MACI® (autologous cultured chondrocytes on porcine collagen membrane) patient Dara Torres.
The presentation will be live webcast at http://investors.vcel.com/events-presentations. For those not available to listen to the live broadcast, a replay will be archived until April 10, 2019 and available at http://investors.vcel.com/events-presentations. For more informaton or to RSVP please contact Kelly Mueller at [email protected]. About Vericel Corporation Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two advanced cell therapy products in the United States. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com. Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved. (vcel-corp) Global Media Contacts: Karen Chase Investor Contacts: Lee Stern
|